Figure: 1 Compound F3 and enhanced activity derivative F3-8-60 directly bind to K-RAS Figure: 2 F3 class compounds block RAS…
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein…
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and…
PRINCETON, N.J. and NEW YORK and BENGALURU, India, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization…
Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against SuitSAN DIEGO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Executive…
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,…
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma…
WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of…
PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase…
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune…